Dermira Secures $42,000,000 Series A Financing Round

  • Feed Type
  • Date
    10/20/2011
  • Company Name
    Dermira
  • Mailing Address
    2055 Woodside Road Redwood City, CA 94061
  • Company Description
    Dermira is a development-stage, private biotech company focused on developing and commercializing innovative new therapies in dermatology. Dermira was founded by an experienced management team and owns and licenses a robust pipeline of innovative topical compounds addressing areas of need in dermatology. Our lead product candidate, lemuteporfin (LTS), is currently in clinical trials for acne.
  • Website
    http://www.dermira.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Funds will be used to advance the product pipeline, specifically, lemuteporfin, a potent and selective topical photodynamic therapy (PDT) for acne, licensed from QLT Inc., as well as a robust pipeline of novel, topical small molecule therapeutics for sebaceous gland hyperactivity and inflammatory skin diseases.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Canaan Partners